“Latest Stem Cells News”

Italy is the top country in the world for hematopoietic stem cell transplants per million inhabitants, said Alessandro Nanni Costa, the director of the National Transplant Center (CNT), presenting data today in Rome from a study by the Welfare Minister on umbilical cord stem cells.

Italy boasts a registry of 370,000 healthy adults available to donate blood stem cells.

The units of umbilical cord blood preserved in Italian biobanks number 17,503, while in 2008, only 141 were used in Italy or abroad.

The objective is to reach 80,000-90,000 units of umbilical cords preserved from which blood stem cells can be removed for transplants. In Italy there are 18 biobanks for the conservation of umbilical cords that must be reorganize and expanded to reach areas where there are no centers, such as Sardinia.

Incoming search terms:

Patients suffering from blindness now need not wait for donors as doctors have found a way to treat many with the stem cells derived from the cornea of a dead body.
Doctors at the AIIMS and a private clinic in the national capital are using corneal surface stem cells from a cadaver’s (dead person) eye for curing corneal injuries in many.

“We have used the corneal surface stem cells of cadaver’s eye for patients with corneal injury and have been able to correct many vision,” Dr Radhika Tandon, Associate Professor, Department of Opthalmology, AIIMS said, adding “this has been done on over more than 100 patients of corneal injury.” Usually, the standard practice has been a corneal transplant from human cadaver. But due to shortage of donors, doctors have become more specific in their mode of treatment.

The technique has come as a divine blessing to many patients, Tandon said.
“Instead of a whole cornea for one patient, we check the level of injury and use stem cells instead. This way we can help even four patients with one cornea,” Dr Asim Kumar Kandar, Consultant, Centre for Sight, said.
Stem cells exist in various regions of the eye but so far, they can be found at the outer edges of the cornea, he said.

Incoming search terms:

Just as Barack Obama has loosened the regulations on embryonic stem cell research in the USA, the Austrian Commission of Bioethics (which advises the government) has decided to implement more liberal regulation. Today in Austria it is prohibited to produce embryonic stem cells, but it is allowed to import them from abroad. These cells are expensive and research is hindered by high costs. The majority of the Commission has advised, with a 17 to 5 vote, that the use of excess embryonic stem cells from assisted fertilization procedures be made legal. If they are not used, after a certain period of time, the embryos are disposed of, and therefore it makes more sense to use them for research. The council rejected a possible production of embryos specifically to be used for research.

Incoming search terms:

Preston Walker and Richard Humphries are shining examples of how stem cell research using Adult Stem Cells are improving lives right now. Preston and Richard were the first two Multiple Sclerosis patients to receive stem cell treatment with their own cells derived from their fat.

Stem Cell Treatment in the USA? Of Course Not

The treatment and therapy took place in May 2008 in Costa Rica and since then the duo have generously donated their time to other Multiple Sclerosis patients who were in the same boat Richard and Preston were in approximately 1 year ago.    They are also spreading the word that Adult Stem Cells can help Multiple Sclerosis now with a treatment that is simple with no side effects.

A Note From Richard Humphries -Multiple Sclerosis Adult Stem Cell Treatment

Recently Richard wrote this regarding his own stem cell therapy:

Myself and Preston Walker were the first to receive the fat cell derived stem cell treatment in hopes of leveling off our immune system which has successfully happened without the severe side effects of chemo which has shown not as successful as the adipose treatment much less the unneccessary expense.

I’m case study #1 in the paper (Multiple Sclerosis Study) just released and have had two stem cell treatments in Costa Rica where they promise nothing but deliver wonderful results. Secondary Progressive Multiple Sclerosis patients can’t wait on historical data. Time is not on our side but stem cells improved my quality of life and the follow up MRI looks excellent.

Richard Humphries

Stem Cell Treatment Enables Police Sergeant to Patrol Again

And then Preston Walker wrote this email to another Multiple Sclerosis patient who was considering using the stem cell research and therapy that changed his life:

I received the treatment in Costa Rica in May 2008. My symptoms included fatigue, depression, a cognitive cloud, foot drop and heat intolerance. At the time I went, I was taking features , Wellbutrin XL, Provigil and Razadyne.

The only thing I am taking now is Avonex as a maintenance drug. I am free of the fatigue and depression. I still have a cognitive cloud but it is nothing like it was before the treatment!

I am a police Sergeant in Fort Worth, TX. I am assigned to patrol and wear a dark blue uniform. If it wasn’t for the treatment, I don’t think I would make it to retirement in a few years. I feel absolutely certain that I will continue my active lifestyle and my career.

You can read the full story on the Fort Worth Star-Telegram’s website (www.startelegram.com). Once you get to the homepage, click on the BLOGS link. Once the next page loads, click on My Fight with MS in the bottom right hand corner. If you will go from the beginning by looking at the May 2008 folder in the archives (left hand side of the page), you will get a better idea of my journey while in Costa Rica. I underwent the treatment with Richard Humphries who posted while we were there also.

I will not tell you I am cured, but I am virtually symptom free!! My quality of life improved exponentially after the treatment.

If I can be of any further help, don’t hesitate to ask.

Preston Walker

The Debate on Stem Cell Research – Why So Much Emphasis On Cures?

Are people getting so caught up on the stem cell research issue that we are ignoring the patients who are in need of help right now? When the issue of stem cell research comes up, we always hear about promised cures. Are we so intent on 100% “cures” that we ignore stem cell treatments that are not “cures”, but do indeed help improve the quality of lives of the majority of patients right NOW. I’m sure Richard and Preston above are very happy with their results. Is their Multiple Sclerosis cured? No, it wasn’t a “cure”. Does that mean it isn’t good enough?

Why do we have to go for the homerun on every at bat, when a patient would be grateful for a single or double? Would Michael J Fox be happy if his Parkinson’s symptoms subsided for 5 years like this gentleman?

I see endless articles and letters to the editor that support state or federal taxes for Adult Stem Cell research or Embryonic Stem Cell research, but rarely do I see an article or letter promoting USING the only treatment that works now- Adult Stem Cells.  In the end, with all this hoopla, we are forgetting about what should be the reasons for the debates and research in the first place- the patients.

Remember, there are no side effects from using your own stem cells, either they help (most of the time) or they don’t (no harm done).

Perhaps we should take aim at the FDA as they are responsible for classifying a patient’s own stem cells as a drug thus forcing decades of clinical trials and sentencing millions of patients to unnecessary suffering and deaths by withholding the use of something that could help improve patients’  lives with very little risks.  Preston and Richard were lucky in that they had the resources and the courage to travel outside the box that is the FDA’s jurisdiction.  Millions others are not so lucky.

Incoming search terms:

CD133 (Prominin) is widely used as a marker for the identification and isolation of neural precursor cells from normal brain or tumor tissue. However, the assumption that CD133 is expressed constitutively in neural precursor cells has not been examined.

Methodology/Principal Findings

In this study, we demonstrate that CD133 and a second marker CD15 are expressed heterogeneously in uniformly undifferentiated human neural stem (NS) cell cultures. After fractionation by flow cytometry, clonogenic tripotent cells are found in populations negative or positive for either marker. We further show that CD133 is down-regulated at the mRNA level in cells lacking CD133 immunoreactivity. Cell cycle profiling reveals that CD133 negative cells largely reside in G1/G0, while CD133 positive cells are predominantly in S, G2, or M phase. A similar pattern is apparent in mouse NS cell lines. Compared to mouse NS cells, however, human NS cell cultures harbour an increased proportion of CD133 negative cells and display a longer doubling time. This may in part reflect a sub-population of slow- or non-cycling cells amongst human NS cells because we find that around 5% of cells do not take up BrdU over a 14-day labelling period. Non-proliferating NS cells remain undifferentiated and at least some of them are capable of re-entry into the cell cycle and subsequent continuous expansion.

Conclusions

The finding that a significant fraction of clonogenic neural stem cells lack the established markers CD133 and CD15, and that some of these cells may be dormant or slow-cycling, has implications for approaches to identify and isolate neural stem cells and brain cancer stem cells. Our data also suggest the possibility that CD133 may be specifically down-regulated during G0/G1, and this should be considered when this marker is used to identify and isolate other tissue and cancer stem cells.

from Elites TV

Incoming search terms:

Study May be Key to Unlocking a Cure

An article published in the Summer 2009 edition of Multiple Sclerosis Quarterly Report, a joint publication of United Spinal Association (www.UnitedSpinal.org) and the North American Research Committee on Multiple Sclerosis (NARCOMS), highlights the positive initial results of patients who have improving neurologic function after receiving a stem cell transplant, despite no longer taking any MS medications.

The results are reported in a National Institutes of Health (NIH)-sponsored study called HALT-MS to confirm whether high-dose immunosuppression followed by autologous stem cell transplantation will prevent MS attacks in patients who are not responding to available treatment options and ultimately protect against the degeneration of nerve fibers.

The article, written by George H. Kraft, MD, MS, director of the Western MS Center in Seattle, Washington, and colleagues, reveals the promising outcomes of the first three patients entered into the HALT-MS Study, including a 27-year-old woman with an 8-year history of relapsing MS who was treated with five different MS drugs, but continued to have relapses.

The study involves wiping out the patient’s immune system through high-dose chemotherapy or other means, such as radiation, to destroy most blood cells and bone marrow. Blood “stem cells” with the capacity to generate new blood and immune cells are then transplanted into the patient. These stem cells can either be the patient’s own or those from a matched donor. Once the cells are transplanted, they repopulate the bone marrow and restart building all the cell types found in the blood, a process called “engraftment”. After transplantation, the patient would effectively have a “new” immune system that would not attack nerves in the brain and spinal cord as seen in MS.

Currently, there are approximately 400 patients with MS worldwide who have been treated with stem cell transplantation. Research demonstrates that patients with highly active forms of relapsing-remitting MS have responded best to treatment.

The Halt-MS Study is taking place at four centers in the US: The Fred Hutchinson Cancer Research Center/University of Washington Western MS Center; Ohio State University; Baylor College of Medicine; and M.D. Anderson Cancer Center, and is currently open to participants with severe relapsing forms of MS. For more information, visit HALT-MS Website

from PR newswire

Incoming search terms: